SCHEMBL9924246

SCHEMBL9924246

O=C(/N=C(/NCc1ccc(Cl)c(F)c1)N[C@H]1CC[C@H](Nc2ncccn2)CC1)c1ccc(F)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.43
SSTR3 P32745 1/20 0.41
MAPK1 P28482 4/20 0.40
EPHX2 P34913 1/20 0.40
RPS6KA1 Q15418 1/20 0.39
MCHR1 Q99705 7/20 0.39
PPARG P37231 3/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
HTR2B P41595 1/20 0.39
NPY5R Q15761 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
MAPK3 P27361 1/20 0.37
AR P10275 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924253 0.94 MAPK1 (0.43) P2RX7SSTR3MAPK1EPHX2MCHR1
SCHEMBL9924234 0.92 EPHX2 (0.41) P2RX7SSTR3EPHX2MCHR1HTR1A
SCHEMBL9924235 0.87 EPHX2 (0.46) MAPK1EPHX2MCHR1HTR1AADRA2A
SCHEMBL9924269 0.87 SSTR3 (0.45) P2RX7SSTR3MAPK1RPS6KA1MCHR1
SCHEMBL9924245 0.86 EPHX2 (0.49) P2RX7EPHX2MCHR1
SCHEMBL9924151 0.85 EPHX2 (0.48) P2RX7EPHX2MCHR1HTR1AADRA2A
SCHEMBL9924236 0.85 SMYD3 (0.42) P2RX7MAPK1MCHR1ADRA2A
SCHEMBL9924252 0.85 PDE4B (0.42) EPHX2MCHR1HTR1AADRA2AADRA1A
SCHEMBL17206705 0.84 MAPK14 (0.42) MAPK1EPHX2MCHR1HTR1AADRA2A
SCHEMBL9924067 0.82 SMN1; SMN2 (0.43) P2RX7SSTR3MCHR1PPARGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed